NAD+ Peptides

Featured

Also known as: NAD+, Nicotinamide Adenine Dinucleotide

Peptides and molecules that support cellular NAD+ levels for metabolic health.

Overview

NAD+ is a critical coenzyme for cellular energy metabolism and sirtuin activity. Levels decline with age, and restoration through precursors and peptides is a key longevity strategy.

Mechanism of Action

NAD+ serves as electron carrier in metabolism and substrate for sirtuins (SIRT1-7), PARPs, and CD38. Supporting NAD+ levels enhances mitochondrial function and cellular repair.

Pharmacokinetics

Direct NAD+ has limited bioavailability; precursors (NMN, NR) and injection routes preferred for elevation.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

IV Protocol

Dose

250-500 mg

Frequency

Daily

Duration

5-10 days

IV infusion over 2-4 hours

2

Subcutaneous

Dose

50-100 mg

Frequency

Daily

Duration

4-8 weeks

Self-administered maintenance

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Metabolic optimization

Synergy: NAD+ supports MOTS-c AMPK activation

Rationale: Anti-aging

Synergy: Comprehensive cellular rejuvenation

Research Areas

AgingMitochondrial FunctionNeurodegenerationMetabolic Health

Key Research Findings

  • 1NAD+ decline correlates with aging hallmarks
  • 2Restoration improves mitochondrial function in aged mice
  • 3Sirtuin activation linked to longevity pathways
  • 4Clinical trials ongoing for various indications

Side Effects & Contraindications

Reported Side Effects

  • Flushing (IV)
  • Nausea
  • Chest tightness (IV)

Contraindications

  • Active cancer (theoretical)

Safety Considerations

Generally well-tolerated. IV NAD+ may cause flushing, nausea during infusion.

Storage Requirements

Store at 2-8C, protected from light

Scientific References

Quick Reference

Sequence
Coenzyme (C21H27N7O14P2)
Molecular Weight
663.43 g/mol
Half-Life
Variable by form
Bioavailability
Form-dependent
Research Stage
clinical phase 2
Administration
IV, subcutaneous, oral (precursors)